Reduction of cisplatin-induced emesis by a selective neurokinin-1- receptor antagonist

New England Journal of Medicine

Volumn 340, Issue 3, 1999, Pages 190-195

  Navari, Rudolph M ^a   Reinhardt, Rick R ^b   Gralla, Richard J ^c   Kris, Mark G ^d   Hesketh, Paul J ^e   Khojasteh, Ali ^f   Kindler, Hedy ^g   Grote, Thomas H ^h   Pendergrass, Kelly ⁱ   Grunberg, Steven M ^j   Carides, Alexandra D ^b   Gertz, Barry J ^b  

^a Simon Williamson Clinic   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c OCHSNER MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e ST ELIZABETH'S MEDICAL CENTER   (United States)

^f Cap Compreh Cancer Care Clinic   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h Salem Research Group   (United States)

ⁱ Research Medical Center Brookside Campus   (United States)

^j FLETCHER ALLEN HEALTH CARE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; GRANISETRON; L 754 030; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HICCUP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ACETALS; AGED; ANTIEMETICS; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PATIENT SATISFACTION; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0033590464     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199901213400304     Document Type: Article

References (35)

1. Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V. Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-95.
2. Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Quality of life studies in chemotherapy-induced emesis. Oncology 1996;53:Suppl 1:92-5.
3. Laszlo J, Lucas VS Jr. Emesis as a critical problem in chemotherapy. N Engl J Med 1981;305:948-9.
4. Gralla RJ. Controlling emesis in patients receiving cancer chemotherapy. Recent Results Cancer Res 1991;121:68-85.
5. Gralla RJ, Tyson LB, Kris MG, Clark RA. The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 1987;71:289-301.
6. Kris MG, Cubeddu LX, Gralla RJ, et al. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 1996;78:2193-8.
7. Passalacqua R, Cocconi G, Bella M, et al. Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH). Ann Oncol 1992;3:481-5.
8. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Heskcth PJ. Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer 1993;29A:Suppl 1:S35-S38.
9. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108-14.
10. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379-84.
11. Navari RM, Madajewicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multiccnter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995;13:2408-16.
12. Borison HL, McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983;25:Suppl 1:8-17.
13. Ireland SJ, Straughan DW, Tyers MB. Influence of 5-hydroxytryptamine uptake on the apparent 5-hydroxytryptamine antagonist potency of metoclopramide in the rat isolated superior cervical ganglion. Br J Pharmacol 1987;90:151-60.
14. Kris MG, Gralla RJ, Tyson LB, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine: results of consecutive trials in 255 patients. Cancer 1985;55:527-34.
15. De Mulder PH, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study. Ann Intern Med 1990;113:834-40.
16. Kris MG. Phase II trials of ondansetron with high-dose cisplatin. Semin Oncol 1992;19:Suppl 4:23-7.
17. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994;51:113-8. [Erratum, Oncology 1994;51:243.]
18. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8.
19. Smith DB, Newlands ES, Rustin GJS, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991;338:487-90.
20. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994;12:596-600.
21. Roila F, Bracarda S, Tonato M, et al. Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. Clin Oncol (R Coll Radiol) 1990;2:268-72.
22. Hesketh P. Management of cisplatin-induced delayed emesis. Oncology 1996;53:Suppl 1:73-7.
23. Gralla RJ, Rittenberg C, Peralta M, Lettow L, Cronin M. Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. Oncology 1996;53:Suppl 1:86-91.
24. 1 receptor antagonists is mediated centrally in the ferret. Br J Pharmacol 1994;112:Suppl:516P. abstract.
25. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993;73:229-308.
26. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996;35:1121-9.
27. 1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 1996;65:45-53.
28. 1 receptor antagonist PD 154075 blocks cisplatin induced delayed emesis in the ferret. Eur J Pharmacol 1997;321:209-16.
29. 1 receptor antagonist L-754,030 and its N-phosphoryl prodrug L-758,298 inhibit acute and delayed cisplatin-induced emesis in the ferret. Proc Am Soc Clin Oncol 1998; 17:253a. abstract.
30. 1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1997;89:817-8.
31. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
32. Common toxicity criteria, version 2.0. Bethesda, Md.: National Cancer Institute, March 1998.
33. The Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin induced emesis. Lancet 1992;340:96-9
34. Kris MG, Baltzer L, Pisters KMW, Tyson LB. Enhancing the effectiveness of the specific serotonin antagonists: combined antiemetic therapy with dexamethasone. Cancer 1993;72:Suppl:3436-42.
35. Perez EA. Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis. Clin Ther 1996;18: 578-90.